Inflammation: Clinical Trials

108 trials for Inflammation, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

108 terminated. 108 Phase 2, 20 Phase 3, 13 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 2108Terminated 108
Phase 320Terminated 20
Phase 113Terminated 13

Follow Inflammation: new trials by email Literature Review of Inflammation trials Research Report on Inflammation

Trials (filtered) newest first · largest first

All 108 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Transcutaneous Cervical Vagus Nerve Stimulation (tcVNS) in JIA
Active tcVNS, Sham tcVNS - Juvenile Idiopathic Arthritis (JIA)
Phase 2TerminatedNational Institute of Allergy and Infectious Diseases (NIAID)182023-06-272025-11-25
Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant
Xylitol, Placebo - Allogeneic Stem Cell Transplantation
Phase 2TerminatedChildren's Hospital Medical Center, Cincinnati2562023-04-042026-11-02
An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
XPro1595 - Alzheimer Disease, Dementia
Phase 2TerminatedInmune Bio, Inc.112023-02-212026-02-27
Beta-glucan and Fatigue in HSCT Survivors
Beta-glucan, Placebo - Autologous Haemopoietic Stem Cell Transplant
Phase 1 / Phase 2TerminatedUniversity of Florida32023-02-102023-10-24
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
Methadone, Buprenorphine/naloxone, XR-Naltrexone - Opioid-use Disorder, HIV-1-infection
Phase 2TerminatedUniversity of Pennsylvania782023-01-302026-04-07
Colchicine in HFpEF
Colchicine, Placebo - Heart Failure, Inflammation
Phase 2TerminatedMontreal Heart Institute142022-06-172023-04-26
PET Imaging of Cyclooxygenase in Multiple Sclerosis
11C-MC1, 11C-PS13, Ketoprofen - Multiple Sclerosis
Phase 2TerminatedNational Institute of Mental Health (NIMH)72022-06-072024-06-27
The Immunostimulatory Effects of Gentamicin
Gentamicin, Placebo - Healthy Volunteers
Phase 2TerminatedSingapore General Hospital332022-05-112024-05-16
Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients
Canakinumab Injection - Anemia, Myelodysplastic Syndromes
Phase 2TerminatedUniversity of Leipzig102022-04-262024-05-06
A Phase 2a Study, Effect of Vancomycin With vs Without Delpazolid (LCB01-0371) in Patients With MRSA Bacteremia
Delpazolid, Vancomycin, Placebo of Delpazolid - MRSA Bacteremia
Phase 2TerminatedLigaChem Biosciences, Inc.402022-04-262025-05-06
A Prospective, Phase II Study to Evaluate Safety of 101-PGC-005 ('005) for Moderate to Severe COVID-19 Disease Along With Standard of Care
101-PGC-005 ('005) + SOC, Placebo + SOC - COVID-19
Phase 2Terminated101 Therapeutics32022-01-132023-02-24
Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease
Canakinumab, Placebo - Mild Cognitive Impairment, Alzheimer Disease
Phase 2TerminatedNovartis Pharmaceuticals342021-10-282025-10-16
Atorvastatin on Inflammation and Cardiac Function in Chronic Chagas Disease
40 mg Atorvastatin/day for 120 days P.O., Atorvastatin 80, Placebo - Chronic Chagas Disease
Phase 2TerminatedJuan D. Maya3002021-10-122024-09-19
HAT for the Treatment of Sepsis Associated With NASTI
HAT, Placebo - Necrotizing Soft Tissue Infection, Sepsis
Phase 1 / Phase 2TerminatedAscension Health102021-09-102024-07-24
Ceftriaxone to PRevent pneumOnia and inflammatTion aftEr Cardiac arresT (PROTECT)
Standard of care without prophylaxis, Antibiotic prophylaxis - Out-Of-Hospital Cardiac Arrest, Pneumonia
Phase 2TerminatedDavid J. Gagnon532021-08-202025-04-17
Cannabinoids in PLWHIV on Effective ART
TN-TC11M2 oral capsules (THC 2.5 mg/CBD 2.5 mg), TN-C200M2 oral capsules (CBD 200 mg) - HIV Infections
Phase 2TerminatedMcGill University Health Centre/Research Institute of the McGill University Health Centre102021-08-202022-06-30
Safety and Efficacy of Maraviroc and/or Favipiravir With Standard Therapy in Severe COVID-19 Adults
Maraviroc + Currently used therapy, Curently used therapy for COVID-19 non-critical patients, Favipiravir + Currently used therapy - COVID-19
Phase 2TerminatedHospital General de México Dr. Eduardo Liceaga192021-07-132022-06-03
Best Available Therapy With or Without Meropenem for Bloodstream Infections by Enterobacterales With High Level of Resistance to Carbapenems
Meropenem - Carbapenem-Resistant Enterobacteriaceae Infection, Bloodstream Infection
Phase 2 / Phase 3TerminatedHospital de Clinicas de Porto Alegre132021-05-042022-08-03
RAPA-501-Allo Therapy of COVID-19-ARDS
RAPA-501-Allo off-the-shelf Therapy of COVID-19, Placebo - Severe COVID-19 Disease
Phase 1 / Phase 2TerminatedRapa Therapeutics LLC12020-12-302021-11-11
INB03 for the Treatment of Pulmonary Complications From COVID-19
INB03, Placebo - COVID-19
Phase 2 / Phase 3TerminatedInmune Bio, Inc.792020-10-212026-05-19

Showing 20 of 108. Sign in to see all of them.

Narrower conditions

Sepsis (22)  ·  COVID-19 (15)  ·  Cytokine Release Syndrome (15)  ·  Shock, Septic (14)  ·  Coronavirus Infections (7)  ·  Respiratory Distress Syndrome (6)  ·  Bacteremia (5)  ·  Critical Illness (5)  ·  Infections (5)  ·  Alzheimer Disease (4)  ·  Arthritis, Rheumatoid (4)  ·  Heart Failure (3)  ·  Pneumonia (3)  ·  Systemic Inflammatory Response Syndrome (3)

Broader conditions

Pathologic Processes (108)  ·  Pathological Conditions, Signs and Symptoms (108)  ·  Infections (59)  ·  Systemic Inflammatory Response Syndrome (53)  ·  Shock (30)  ·  Respiratory Tract Diseases (22)  ·  Virus Diseases (22)  ·  RNA Virus Infections (19)  ·  Lung Diseases (18)  ·  Coronaviridae Infections (17)  ·  Nidovirales Infections (17)  ·  Sepsis (17)  ·  Respiratory Tract Infections (16)  ·  Pneumonia, Viral (15)

Interventions

Saline Solution (5)  ·  Ascorbic Acid (4)  ·  Sodium Chloride (4)  ·  Standard of Care (4)  ·  Vancomycin (4)  ·  Daptomycin (3)  ·  Meropenem (3)  ·  Colchicine (2)  ·  Etanercept (2)  ·  Fletikumab (2)  ·  Gentamicins (2)  ·  Hydrocortisone (2)  ·  Interleukin 1 Receptor Antagonist Protein (2)  ·  Thiamine (2)  ·  Tranexamic Acid (2)

Sponsors

Amgen (3)  ·  Novo Nordisk A/S (3)  ·  Christiana Care Health Services (2)  ·  Federal University of São Paulo (2)  ·  Imperial College London (2)  ·  Inmune Bio, Inc. (2)  ·  Johns Hopkins University (2)  ·  National Institute of Nursing Research (NINR) (2)  ·  Novartis Pharmaceuticals (2)  ·  Singapore General Hospital (2)  ·  University Hospital, Basel, Switzerland (2)  ·  University of Athens (2)  ·  University of Chicago (2)  ·  University of Florida (2)  ·  101 Therapeutics (1)

Countries

United States (63)  ·  Germany (12)  ·  Canada (11)  ·  France (9)  ·  Spain (9)  ·  Brazil (8)  ·  United Kingdom (8)  ·  Poland (6)  ·  Australia (5)  ·  Belgium (5)  ·  Greece (5)  ·  Italy (5)  ·  Mexico (5)  ·  Switzerland (5)  ·  Czechia (4)

Top investigators

Aaron R Ritter, MD (1)  ·  Adham Mohamed, PharmD (1)  ·  Ajoy C Karikkineth, M.D. (1)  ·  Anand Kumar, MD (1)  ·  Anastasia Kotanidou, MD, PHD, Professor (1)  ·  Anastasia Kotanidou, MD, PhD (1)  ·  Anders Kjellberg, MD (1)  ·  Ann Nguyen, MD (1)  ·  Anne Sophie Kubasch, Dr. (1)  ·  Antonio Cubillo, MD (1)  ·  Axel R. Heller, MD (1)  ·  Beth Gottlieb, MD (1)  ·  Betty Diamond, MD (1)

Results publications

PMID 10722036, PMID 1138591, PMID 11502226, PMID 12454520, PMID 12545007, PMID 12700374, PMID 1607900, PMID 16570523, PMID 18164921, PMID 18353115, PMID 19234342, PMID 20332511, PMID 20459801, PMID 20497755, PMID 20646908, PMID 20844049, PMID 21864392, PMID 22269279, PMID 227054, PMID 23000649, PMID 23525934, PMID 23549582, PMID 24484547, PMID 24794878, PMID 24838355, PMID 24943129, PMID 25466837, PMID 26771781, PMID 26903338, PMID 27162802, PMID 27695824, PMID 27940189, PMID 28098591, PMID 28523582, PMID 28732314, PMID 29247809, PMID 29325753, PMID 29388815, PMID 29555789, PMID 29859132, PMID 30271882, PMID 30659041, PMID 31220256, PMID 31577035, PMID 33397449, PMID 33831327, PMID 34226219, PMID 34473343, PMID 34504196, PMID 34755269

NIH funding

2014 (2), 1UG3DE030401-01 (1), 2018 (1), 2019 (1), K23AG052633 (1), K23HL096054 (1), P20GM139745 (1), P30CA016672 (1), UL1TR001079 (1)